updat combat pancreat cancer
monday manag announc earn provid corpor updat
earli data triplet combin arm trial
pancreat cancer could provid near-term catalyst stock data select
oral present esmo i/o confer dec investig
md anderson present result studi combin
pembrolizumab heavili pre-treat popul respons compar
doublet arm combat believ translat data present support
use chemotherapi triplet combin combat readout may
serv near-term catalyst see pivot genesi trial stem
cell mobil biolinerx primari valu driver reiter outperform pt
triplet arm combat assess pembrolizumab
folfiri chemo regimen wide use second-lin option pancreat
cancer expect earli data could includ respons rate patient
see low efficaci bar set overal respons rate folfiri
biolinerx present data support triplet combin abstract
demonstr synergist effect chemotherapi
activ effector t-cell reduc suppress immun cell xenograft
model triplet outperform doublet combin addit
mobil effect t-cell previous document patient
md anderson abstract featur phase result doublet
combin pembrolizumab therapi yield one pr
heavily-pretr patient view result larg consist
perform doublet arm combat translat data suggest
presenc til avail biopsi may predict clinic benefit
biolinerx pivot genesi trial investig stem cell mobil
remain track deliv top-line data confid trial
meet primari endpoint base compel data prior trial base
comp includ sanofi mozobil believ could achiev peak sale
compani report net loss lower estim net loss
discrep larg due increas non-oper incom
relat fair-valu adjust warrant liabil revis forward
estim biolinerx end cash equival could
sustain oper late top-line data genesi
year price histori blrx
clinical-stag bio-
pharmaceut compani focus
hematolog malign
analyst certif import disclosur see disclosur
rate blrx outperform pt
base risk-adjust revenu ep multipl analys
valuat base commerci potenti
auto-hsct mobil believ result phase
genesi trial could spur major transplant physician
choos mozobil combin g-csf drug
approv upsid thesi includ use allo-
hsct aml solid tumor compani boast catalyst-
rich deep oncolog pipelin attract collabor
novarti merck genentech
genesi readout patient multipl myeloma mm
success bridg studi expand label auto-hsct non-
risk-adjust peak market stem cell
mobil us eu market
potenti interim readout on-going blast studi
potenti interim readout studi tripl
potenti top-lin data phase genesi trial
better expect uptak mobil auto-hsct
expans allo-hsct
clinic success blast and/or battl trial
potenti lead approv aml
clinic success use solid tumor
clinic success earli stage program
clinical/regulatori failur auto-hsct uptak
auto-hsct
compani pursu label expans nhl
limit on-label use patient mm
price target per share deriv discount project revenu ep
risk-adjust target multipl line histor multipl profit biotech compani given current stage
develop stem cell mobil project potenti launch
risk includ clinic regulatori financ competit market price pressur
view blrx stock trade specul appropri risk-toler investor
stem cell mobil
potenti top-line result genesi
oncolog
potenti interim readout blast studi aml consolid
potenti interim readout studi tripl combin cohort
solid tumor
potenti initi safeti result phase solid tumor studi
compani present oppenheim co
sec file oppenheim co research
figur thousand except per share stem cell mobil expens good sold research develop sale market gener administr oper incom incom loss incom incom taxnet incom loss attribut common per share share outstand co inc mark breidenbach blrx outperform
sec file oppenheim co research
figur thousand except per share cash short-term bank prepaid current long-term prepaid properti equip right use intang asset non-curr current matur long-term bank account payabl accrual current long-term bank loan net current non-curr equiti ordinari share capit comprehens accumul stockhold liabil stockhold co inc mark breidenbach biolinerx
close stock price mention compani novemb
